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Editor's Choice e First Results of the Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) Technique for Aortoiliac Occlusive Disease INTRODUCTION According to the Trans-Atlantic Inter-society Consensus document (TASC-II), surgical reconstruction, typically by means of aorto-bi-iliac bypass grafting, is the treatment of choice for extensive aortoiliac occlusive lesions, classified as TASC-II D, and should also be considered in bilateral occlusion of the common iliac arteries (TASC-II C). This is the consequence of the good long-term patency rates after surgical reconstruction. Surgery, however, is associated with both early and late morbidity and peri-operative mortality. Therefore, comorbidities should be taken into consideration when planning a reconstruction for aortoiliac occlusive disease (AIOD). 1 In 1991 the kissing stent technique was introduced as an endovascular treatment alternative for bilateral aortoiliac occlusive disease. In this technique, two stents are placed simultaneously in the common iliac arteries, with an overlap in the distal aorta. 2, 3 Reported technical success rates varied between 89% and 100% with a 1 year primary patency rate between 76% and 98% with the use of bare metal stents (BMS) in TASC-II C and D lesions. 4 Variations in patient and lesion characteristics and techniques used may have caused the variation in outcome.
Covered stents may increase patency rates in extensive disease, as shown by the COBEST trial and confirmed in various case series. 5e9 The COBEST trial showed that covered balloon expandable stents (CBES) have a superior primary patency rate and clinical improvement outcome at 24 months when compared with bare metal stents. 9 In addition CBES may immediately treat or reduce the risk of procedural complications such as dissection, perforation, and embolization, with potential for reducing morbidity and mortality.
The Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) technique was developed in an attempt to overcome the anatomical and physiological disadvantages of kissing stents. 10 Patency rates of kissing stents may be influenced by geometrical factors such as radial mismatch, defined as the perfused dead lumen space around the stents, protrusion mismatch defined as the overlap distance of the stents in the distal aorta, and stent conformation. All these factors may cause flow disturbances leading to re-circulation, turbulence, and stasis of blood, which in turn, may cause thrombus formation and intimal neohyperplasia. 11e14 A recent in vitro geometrical study showed superior stent conformation and lower radial mismatch in the CERAB configuration when compared with the kissing stent configuration. 15 In the present study the first clinical results of the CERAB technique are presented.
METHODS

Patients
Consecutive patients treated between February 2009 and March 2014 using the CERAB technique were prospectively gathered in a database and retrospectively analyzed. Permission was obtained from the institutional review board.
Patients were treated in two hospitals: Rijnstate Hospital Arnhem, the Netherlands and ZNA Clinics, Antwerp, Belgium. Patients with acute limb ischemia were excluded from this analysis, as were patients treated with chimney configurations. Anatomical suitability for the CERAB procedure was assessed using computed tomography (CT) angiography. In all patients cardiovascular risk reduction was performed, including prescription of anti-platelet therapy (in the absence of anti-coagulant therapy) and statins if indicated. All patients treated for intermittent claudication were initially treated with (supervised) walking exercise and considered for treatment only if symptoms persisted and were disabling.
Demographics, clinical status, medical history, and procedural aspects were noted. The clinical status was assessed using the Rutherford Classification for chronic ischemia. 16 Comorbidity was scored according to the Society for Vascular Surgery and American Association for Vascular Surgery medical comorbidity scoring system. 17 CT images were reviewed and scored according to the TASC-II criteria. 1 Routine follow up included clinical assessment, ankle brachial index (ABI) measurements, and duplex ultrasound scans at 1, 3, 6, and 12 months, and annually thereafter. Complications and additional treatments were registered in the hospital files.
Technique
Details of the CERAB technique have been described previously. 10 Briefly, patients were treated either in a hybrid operating theater or in a catheterization laboratory. Two introducer sheaths were introduced (9Fr and 7Fr) into the common femoral arteries, either percutaneously or by surgical cut down. Heparin (5,000 units) was administered to all patients. The occlusive lesion was then passed, either subintimal or endoluminal, using regular catheters (Super Torque, Cordis Corporation, Miami Lakes, FL) and a Terumo wire (Terumo Medical Corporation, Elkton, MD). After gaining re-entry into the lumen of the aorta, angiography confirmed proper positioning for those with a subintimal passage ( Fig. 1A) . A 12 mm V12 LD balloon expandable ePTFE covered stent (Atrium Medical, Maquet Getinge Group, Hudson, NH) was expanded in the distal aorta approximately 20 mm above the bifurcation through the 9 Fr sheath. The proximal 2/3 part of the aortic stent was flared with a larger balloon, usually 16 mm, thereby creating a funnel shaped covered stent. Subsequently, two covered CBES were placed proximally in the distal 1/3 of the aortic stent (consequently the part of the covered stent that was still 12 mm in diameter) and distally into the common iliac arteries and were deployed simultaneously ( Fig. 1B) . Typically, two V12 balloon expandable ePTFE covered stents (Atrium Medical, Maquet Getinge Group, Hudson, NH) with a diameter of 8 mm were used, with these two stents creating a tight connection with the first aortic stent, thereby creating the new aortic bifurcation (Fig. 1C ). When required, distal extensions were added. The sheaths were removed from the common femoral artery and the puncture sites were closed, usually using a closure device (Angio-Seal, St. Jude Medical, St. Paul, MN or Perclose/Starclose, Abbott Vascular, Abbott Park, IL) or sutured in cases of open introduction. Concomitant endarterectomy of the femoral artery or external iliac artery was performed in cases of multilevel disease. Patients received standard statin treatment and dual anti-platelets for 6 months followed by mono-therapy, unless oral anti-coagulation was indicated for other reasons.
Definitions
The primary outcome measure was 1 year primary patency. Secondary outcomes were technical success, length of hospital stay, morbidity, mortality, clinical improvement, secondary patency, and limb salvage.
Classifications were used according to the reporting standards. 16, 18 Technical success was defined as stent placement restoring blood flow with <30% residual stenosis. Primary patency was defined as uninterrupted patency in the absence of re-stenosis or occlusion, without any procedures performed on the vessel or stent. Secondary patency was defined as patency achieved by all procedures aimed at recanalizing an occluded CBES, thereby preserving the endograft. Freedom from target lesion revascularization (TLR) was defined as an open endograft without procedures performed for re-stenosis or occlusion leading to symptoms requiring an intervention. Criteria for re-intervention included clinical deterioration based on occlusion or stenosis, or stent collapse.
Clinical improvement was defined as a hemodynamic improvement with and increase of at least 0.10 in ABI, combined with a symptomatic improvement of at least one Rutherford category. Re-stenosis was defined as a lesion with a peak systolic value (PSV) ratio !2.5 as measured in the endograft and proximal or distal to the endograft or an angiographic diameter reduction of >50%. 18, 19 Limb salvage rate was defined as all patients without above ankle amputations. Minor complications were defined as those that were only temporary leading to impairment, whereas major complications were defined by permanent damage or death.
Statistical analysis
Variables were expressed as mean AE one standard deviation (SD) in case of normal distribution, or median plus range in other distributions. In all patients the mean ABI of both legs was calculated to compare pre-and postprocedural ABI with paired t tests.
Patency and limb salvage rates were estimated using the Kaplan-Meier survival analysis on a per patient basis. To test for survival differences, analyses with the log-rank (Mantel-Cox), or the generalized Wilcoxon (Breslow) tests were used. Probability values given are based on two sided analyses of test results. A significance level of 5% was used. Statistical analysis was performed with SPSS version 19.0 (Statistical Package for the Social Sciences, Inc., Chicago, IL).
RESULTS
One hundred and three patients (51 male, 52 female) underwent a CERAB procedure for chronic ischemia during the study period and were included in this study. Five other patients were treated with a CERAB configuration for acute ischemia in this period but were excluded from this analysis, as were five patients who were treated with chimney grafts in the inferior mesenteric artery or renal artery in combination with a CERAB. During the study period 32 other patients were treated with a surgical bifurcation prosthesis. The median age of the study group was 61 years (range 36e 85 years). Patient characteristics and co-morbidities are listed in Table 1 .
The indication for treatment was disabling claudication in 64 patients (62.1%) and critical limb ischemia in 38 patients (36.9%) ( Table 1) . One patient was classified as Rutherford Category 1. He was treated for an aorto-bi-femoral bypass at risk for occlusion because of subtotal stenosis at the proximal anastomosis of this bypass. The median follow up was 12 months (range 0e49 months). There was no 30 day mortality, but eight patients died during follow up. Six patients died as a result of non-procedure related causes (Table 2) , and in the other two patients the cause of death was unknown. Duplex follow up at 6 months was available for 74 patients, at 1 year for 52 patients, and at 2 years for 29 patients.
In 69 patients (67.0%) this was the first procedure performed in the aortoiliac segment, 26 patients (25.2%) had previously undergone endovascular procedures in this segment, including stent placements in 17 patients. Eight patients (7.8%) had earlier surgical reconstructions, including four aorto-bi-iliac bypasses and two aorto-bifemoral bypasses. The lesion characteristics are shown in Table 3 . Most patients were treated for TASC-II D lesions.
Procedural outcome
Technical success was achieved in 98 patients (95.1%). Reasons for technical failure included three cases in which the guidewire could not be passed because of heavily calcified lesions, in one procedure the guidewire could be advanced, but the sheath could not pass the lesion and in one case re-entry into the lumen could not be achieved. In two of these patients a surgical bypass was constructed by means of an aorto-bi-iliac bypass and an ilio-femoral crossover bypass. In another patient, a second attempt was successfully performed (with growing experience) 2 years after the first procedure. The fourth patient, suffering from focal tissue loss, died 48 days after the attempt and before a secondary treatment could be performed.
Seventy-seven procedures (74.0%) were performed percutaneously, and 27 (26.0%) were performed by surgical cut down (18 one site, 9 both sites). In 21 of them the procedure was combined with an endarterectomy of the common femoral artery and/or distal external iliac artery. In five patients an additional PTA was performed in the external iliac arteries, in one patient followed by stent placement. In one case thrombectomy of an occluded limb of a bi-femoral bypass was performed. In one patient the femoral artery occluded during the procedure, with resolution after thrombectomy.
In 60.6% the CERAB configuration consisted of a 12 mm aortic stent either 61 mm (N ¼ 22) or 41 mm (N ¼ 38) in length and two 8 Â 59 mm iliac stents. In 65.7% of the successful procedures the CERAB was completed with the use of three covered stents, as the technique was initially First Results of the CERAB Technique described. The remainder required distal extensions to cover the entire diseased segment. Stent specifications are listed in Table 3 .
Procedural complications included 10 dissections, of which six were treated with balloon angioplasty alone and three with an additional stent. One dissection was left untreated as it was not flow limiting (Table 4 ). There were two iliac artery ruptures. One was covered by CERAB itself and the other with a self expanding covered stent. In one case, already mentioned above, thrombus formation occurred for which a thrombectomy was performed. In two early cases a stent dislodged from the balloon. In one the dislodged stent was placed in the external iliac artery and in the other it was used as an additional proximal stent in the aorta. The overall procedural complication rate was 14.6%. All complications, except the surgical thrombectomy, were resolved endovascularly and did not lead to any permanent deficit.
In three patients a patent internal iliac artery was intentionally occluded to treat concurrent occlusive disease of the external iliac artery. In two patients the contralateral internal iliac artery remained patent and in the third patient it was already occluded.
Clinical outcome
Thirty day post procedural complications are listed in Table 4 . There were 22 minor complications and two major complications. Minor complications included 16 groin hematomas, which were left untreated. There were two pseudo-aneurysms treated with thrombin injection and compression bandage, respectively. There was one rebleeding which was conservatively treated with a compression bandage. One patient developed atrial fibrillation treated medically. During the post-operative course two patients developed fever of unknown origin and both were treated with antibiotics. Major complications included one patient with deterioration of chronic renal insufficiency after the procedure. The calculated glomerular filtration rate decreased from 53 to 36 mL/min/ 1.73 m 2 . Eventually, this patient required permanent dialysis 1 year after the procedure. One patient developed a bilateral pneumonia and died 5 weeks after the procedure. The 30 day overall complication rate was 23.3%, the major complication rate was 1.9%, and the 30 day mortality was 0%. Median duration of admission was 2 days (range 1e16 days). Twenty-one patients (20.3%) were admitted to an intensive care unit for the median duration of 1 day (range 1e3 days).
The mean ABI, measured bilaterally, significantly improved from 0.64 AE 0.21 before the procedure to 0.91 AE 0.14 after the procedure (p < .001). The highest measured ABI before the procedure improved from 0.71 AE 0.25 to 0.93 AE 0.14 after the procedure, measured using the same leg. Clinical improvement with at least one Rutherford category occurred in 89 of 96 patients (92.7%) at 6 months after the procedure. In the remaining three patients with technically successful CERAB no postprocedural Rutherford category was documented. The patients who did not improve included the patient with Rutherford 1, who was treated for a bypass at risk. One patient had no improvement because of a persistent dissection distal to the additional stent which was placed during the procedure. She was treated by further stent placement, 3 months after the CERAB procedure. Two patients had a stent collapse/severe kinking of one of the iliac stents at day 21 and day 30, respectively. One patient underwent kissing balloon PTA and the other patient converted to an aortic-bi-iliac surgical bypass as the patient First Results of the CERAB Technique refused further endovascular treatment. One patient did not improve because of a short occlusion of the common femoral artery for which an endarterectomy was performed 5 months after the CERAB procedure. Another patient did not improve because of multiple stenoses in the superficial femoral artery for which balloon angioplasty was performed. In one patient, treated for severe claudication, the CERAB was extended to the external iliac artery for a stenosis distal to the stent after a month, without clinical improvement. The patient died before another reintervention could be performed.
Patency rates
The primary patency rate at 6 months was 90.2%, at 1 year 87.3%, and at 2 years 82.3% (Fig. 2) . At 6 months the secondary patency rate was 96.5%, 95.0% at 1 year, and 95.0% at 2 years (Fig. 2) . Freedom from TLR was 92.4% at 6 months, 88.2% after 1 year, and 85.6% at 2 years (Fig. 2) .
Univariate analysis showed no significant influence of smoking, diabetes mellitus, hypertension, dyslipidemia, renal disease, coronary artery disease, or carotid disease on the primary patency rates. There was no difference in the primary patency between patients treated for critical limb ischemia or intermittent claudication (p ¼ .90). There was also no significant difference between patients who were primarily treated with CERAB and those who underwent previous intervention (p ¼ .44) (Fig. 3 ). There were no differences in primary patency rate between the first 20 patients treated in each clinic, compared with the patients treated thereafter (p ¼ .33). In 15 patients (15.3%) there was loss of primary patency during follow up. Ten patients had re-stenosis, of which three were caused by kinking of one of the iliac stents or stent collapse. These patients were treated by PTA and in one case by additional stent placement. The other seven patients developed a stenosis above the aortic stent (N ¼ 1) or distal to the iliac stents (N ¼ 6), referred to as edge stenosis. Two cases were not treated as the patients were symptom free, in three cases the iliac limb was extended with an additional CBES, and in the other two cases a PTA was performed. Five CERABs occluded, of which, one occurred after the patient stopped the anti-platelets. In two patients, treated with surgical thrombectomy and fibrinolysis, respectively, an outflow stenosis was found in the external iliac artery and treated by PTA in one case and an extra CBES in the other. In one patient there was a stent collapse of one of the iliac CBES. No cause was identified for the occlusion in the last patient. The latter two were treated with a surgical bypass. Loss of primary patency occurred in nine patients within the first 6 months of the procedure and in two patients after 2 years. The limb salvage rate was 100%.
DISCUSSION
In this study the first results of the CERAB technique are presented, which confirm the safety and efficacy of this new endovascular approach for extensive and complex occlusive lesions of the aortic bifurcation. To date, surgical reconstruction has been the gold standard for the treatment of TASC-II C and D lesions according to the TASC-II guidelines. 1 By mimicking the aortic bifurcation anatomically and physiologically, CERAB might improve the patency rate of endovascular techniques and also reduce the risk of severe complications when compared with surgical reconstruction. The technique may be a valid alternative to current treatment modalities.
Calculated primary patency rates of the CERAB procedure in this study cohort are 87.3% at 1 year and 82.3% at 2 years. These primary patency rates appear to be at the same level as have been described for kissing stents. However, many patients in the present study, in contrast with the kissing stent series, were treated for the more complex TASC-II D lesions. The published kissing stent series usually consist of mixed populations treated for all TASC lesions and treated for different indications. In a recent review, it was shown that the indications for treatment with kissing stents varied greatly, from 33% to 100% of patients treated for claudication. 20 In the present study 36.9% of the patients were treated for critical limb ischemia. In addition, the incidence of TASC A and B lesions treated with kissing stents varied from 0% to 92%, rendering comparisons unfair with the present group of patients, who were mostly treated for TASC-II D lesions. Another point of interest is the definition of loss of primary patency used. This study used a definition that included re-stenosis, as was also used by Sabri et al. in their historical cohort study on kissing covered stents. 8 This is in contrast with the outcomes presented by Humphries et al., where primary patency was only affected by stent occlusion or re-interventions. 21 In the present authors' opinion, re-stenosis is an important outcome of endovascular procedures and should be taken into account, as Diehm et al. have suggested. 18 Re-interventions performed to improve or preserve outflow will decrease primary patency rates. As two patients developed occlusions based on outflow impairment, the present authors advocate treatment of stenosis in the iliac tract aggressively to prevent occlusions. This may lead to an increased incidence of re-interventions, even in the absence of symptoms. Secondary patency rates were excellent, 95.0% at 2 years. This implies greater durability of CERAB when preventive re-interventions are performed. In examining re-interventions performed for clinical symptoms (e.g. freedom from TLR), patency rates were 88.2% at 1 year and 85.6% at 2 years.
Loss of primary patency was affected by three major causes. The first and most important reason was stenosis resulting in outflow obstruction. This emphasizes that it is essential to cover the entire stenotic area, with special attention to the distal end before deployment. Otherwise the atherosclerotic lesion may advance distally, resulting in an edge stenosis. The present authors advocate covering the disease from healthy to healthy areas, although intimal disease will always be present in atherosclerosis. Second, four cases of stent collapse or kinking of the iliac tract were observed. In three cases the collapse was situated at the point of crossing of the iliac stents, at the level of the cuff of the aortic stent, thereby pointing at a weakness of the present technique. Another collapse occurred in a 6 mm stent distal to the aortic cuff, at the origin of the native iliac artery. It is possible that highly calcified lesions overcome the radial force of the CBES, especially in small diameters, and improvement in stent design could be used to solve this problem. One patient had an occlusion possibly related to poor therapy compliance. This underlines the importance of the use of anti-platelet or anti-coagulation therapy. In the present study protocol, all patients were treated with antiplatelet therapy, including clopidogrel during the first 6 months and lifelong acetyl salicylic acid (with the exception of patients treated with anti-coagulants such as acenocoumarol or warfarin for other indications). In a high flow reconstruction, however, single anti-platelet therapy might be adequate, but no scientific argument is provided for this in this first case series.
In the present study all patients were included from February 2009 to March 2014. As patency curves did not differ significantly after the treatment of 20 patients, a learning curve was not found to be a factor that affected the results. One would expect that with growing experience results would improve, however, with growing experience the indication for CERAB was expanded in both hospitals to patients with more and more complex lesions, which could possibly have affected results negatively, thereby hiding a learning curve effect. The effect of experience is shown in a patient who underwent a successful CERAB procedure, 2 years after an initial failure. In both clinics, an endovascular first strategy is now applied and surgical bypass grafting is reserved for those patients in whom a CERAB cannot be performed. Now, no patients are excluded for CERAB based on pre-operative imaging. Nevertheless, in very complex lesions in low risk patients, open surgery is always considered. The kissing stent technique has mostly been abandoned.
When treating an occlusion it may be difficult to determine whether the guidewire is advanced intraluminally or subintimally, but as the entire lesion is covered with CBES, this is not clinically relevant. Re-entry to the vascular lumen is always made as distal as possible in the patent aorta. When renal arteries or even visceral arteries are involved in the diseased segment, the use of protective balloons or chimney grafts may be considered.
One of the advantages of the use of CBES is that it might prevent or immediately treat procedural complications such as rupture and distal embolization. There were no clinical signs of distal embolization in the present series. The two ruptures that occurred during procedure were both treated endovascularly, one with the CERAB itself. Other complications during the procedure could all be treated endovascularly, without clinical consequences for the patient making the procedure extremely safe. Patent lumbar collaterals may be occluded by the covered stents, but in the present cohort no patients had symptoms of spinal cord ischemia.
Two major complications occurred for a major complication rate of 1.9%. In one patient, pre-operative impaired renal function worsened after treatment, ultimately leading to hemodialysis after 1 year. This underlines the importance of peri-operative measures to reduce the risk of contrast induced nephropathy. The other major complication consisted of a bilateral pneumonia. This patient was admitted from the department of cardiology and was deemed unfit for a surgical bypass procedure because of cardiac and pulmonary comorbidity. After 3 days of post-procedural observation in the ICU, he was re-admitted to the department of cardiology where he developed a bilateral pneumonia. Eventually the patient died 5 weeks after the procedure. This demonstrates the vulnerability of this group of patients. Most of the observed complications in the present cohort were minor hematomas in the groin. In cases of percutaneous access two types of closure devices were used, but the significance of this cannot be assessed as it was not in the scope of the present study. The close observation of the present population treated with a new technique, also reflected by the high ICU admission in the early experience, may explain the relatively high incidence of hematomas. Overall, CERAB seems to be associated with a lower major morbidity rate compared with surgical reconstruction, but this should to be established in a randomized trial.
CBES are more expensive than bare metal stents and therefore the cost-effectiveness of the CERAB procedure is unclear and needs to be addressed. The need for reinterventions may even increase costs in the long term. However, the low morbidity and mortality compared with surgical repair also reduces costs with regard to in hospital and ICU stay. Moreover, the long-term morbidity of surgical repair, including incisional hernia and adhesion formation with the risk of small bowel obstruction, is accompanied by high costs as well, but these are often neglected. With CERAB the in hospital stay is short with a median hospital stay of 2 days. The first patients treated were observed post-operatively in the ICU according to the protocol of aortic bifurcation reconstructions. Meanwhile, the protocol has changed for endovascular reconstructions. Therefore, the 20.3% ICU admission appears to be a large overestimation of the need for close hemodynamic observation. Observation at a so called medium care facility could provide an alternative; however, one of the hospitals included in this study does not have such a unit. From the last 60 patients treated, only nine were observed in the ICU, for cardiac or pulmonary reasons. Given the low morbidity rate, treatment on an outpatient basis could be justified. It may be possible to abandon the annual duplex ultrasound when the technique has proved its safety in the long term.
This study is limited by being retrospective, therefore the results are likely to be affected by selection bias. Some data are lacking, such as the occurrence of symptoms of buttock claudication or erectile dysfunction after the procedure, which could not reliably be retrieved from the databases. Furthermore, follow up of 2 years was not completed for the entire cohort. The standard error of estimated patency rates at 2 years was 4.9%, confirming the reliability of the calculated patency rates. This study presents the first world experience with the CERAB technique, and long-term data are required before the technique can be considered the new standard.
A randomized controlled trial with prolonged follow up to compare surgical bypass procedures, the kissing stent technique, and CERAB for TASC-II D lesions is indicated to compare morbidity, outcome, and cost-effectiveness. The feasibility of such a study is low however, because of the relatively low incidence of these lesions and as the comorbidity in many patients could drive the physicians towards an endovascular preference, to reduce morbidity and mortality.
CONCLUSION
The CERAB technique is a safe and feasible alternative to open surgical reconstruction of the aortic bifurcation in complex AIOD. Comparative studies with the current gold standards are indicated to define the role of this technique in the treatment algorithm of TASC-II C and D lesions. Critical issues include long-term patency rates, costeffectiveness, patient selection, fine tuning of the technique, and definition of optimal medical support.
CONFLICT OF INTEREST
PG and CZ receives speaker's fees from Maquet. MR receives speaker's fees from Maquet and received research grants from Maquet. For the remaining authors, none were declared.
